Table 1.
Information of patients.
Table 2.
Growth kinetics of HCC cell lines.
Figure 1.
Chromosome analysis of 7 new HCC cell lines.
The median centromere showed human cell origin. Magnification, ×1000.
Table 3.
Quantification of chromosome aberrations.
Table 4.
DNA fingerprinting analysis using 9 STR loci for newly established 7 HCC cell lines.
Figure 2.
Immunohistochemical stain of the new HCC cell lines.
6 tumor related biomarkers were visualized by special antibodies using DAB methods in all 7 new HCC cell lines. IgG was negative control. Magnification, ×400.
Figure 3.
mRNA expression level of some tumor related genes in new cell lines.
A, mRNA expression of βcatenin was up-regulated in all cell lines except LIXC003. LIXC006 cell expressed cMET mRNA significantly higher than HL 7702, while it was opposite in LIXC011. B, mRNA expression of p27kip1 was down-regulated in LIXC002, LIXC003 and CPL0903 cell lines, but up-regulated in LIXC006 and LIXC012 cell lines. LIXC004, LIXC006 and LIXC012 expressed significantly higher PTEN mRNA than HL 7702. C, BCL2 and RAI3 mRNA was down-regulated in all cell lines. Data are expressed as the fold expression relative to the control HL 7702 cell and represented the mean ± S.D. of three individual experiments. *, P<0.05 compared with HL 7702 cell.
Table 5.
In vitro anti-proliferation assay in HCC cell lines.
Figure 4.
Tumor growth curve of LIXC006 and LIXC012 in tumorigenicity test, H&E staining of xenograft tumors and anti-tumor efficacy of sorafenib.
Tumor volume was monitored twice a week. A, tumor growth curve of LIXC006 cells; B, tumor growth curve of LIXC012 cells. C, tumor tissue of LIXC006 cell, tumor cells were crowded together; D, tumor tissue of LIXC012, many blood vessels were inside tissue. Magnification, ×200. E, effect of sorafenib on xenograft tumor of LIXC006; F, effect of sorafenib on xenograft tumor of LIXC012. Data were presented as the mean ± SEM. n = 10.